ROCM Rochester Medical Corp. (MM)

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2009

OR

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                      to                     

Commission File Number: 0-18933

ROCHESTER MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

MINNESOTA State or other jurisdiction of incorporation or organization)		41-1613227 (I.R.S. Employer Identification No.)
ONE ROCHESTER MEDICAL DRIVE, STEWARTVILLE, MN (Address of principal executive offices)		55976 (Zip Code)

(507) 533-9600
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

þ  Yes      o  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

o  Yes      o  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act (check one):

Large accelerated filer  o

Accelerated filer  þ

Non-accelerated filer  o (Do not check if a smaller reporting company)

Smaller reporting company  o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

o  Yes      þ  No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

12,075,367 Common Shares as of August 7, 2009

 

 

Table of Contents

ROCHESTER MEDICAL CORPORATION

Report on Form 10-Q
for quarter ended
June 30, 2009

			Page
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets — June 30, 2009 and September 30, 2008			1
Condensed Consolidated Statements of Operations — Three and nine months ended June 30, 2009 and 2008			2
Condensed Consolidated Statements of Cash Flows — Nine months ended June 30, 2009 and 2008			3
Notes to Condensed Consolidated Financial Statements			4
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			10
Item 3. Quantitative and Qualitative Disclosures about Market Risk			15
Item 4. Controls and Procedures			15
PART II. OTHER INFORMATION
Item 6. Exhibits			16
EX-31.1
EX-31.2
EX-32.1
EX-32.2

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

ROCHESTER MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

		June 30,				September 30,
		2009				2008
Assets:
Current assets:
Cash and cash equivalents		$	5,342,272			$	8,508,000
Marketable securities			29,660,699				28,493,648
Accounts receivable, net			6,000,332				6,009,023
Inventories, net			9,696,882				8,745,873
Prepaid expenses and other assets			892,629				1,110,291
Deferred income tax asset			1,561,510				1,143,931
Total current assets			53,154,324				54,010,766
Property and equipment:
Land and buildings			7,838,840				7,696,076
Equipment and fixtures			16,738,720				16,086,643
			24,577,560				23,782,719
Less accumulated depreciation			(14,836,488	)			(13,899,390	)
Total property and equipment			9,741,072				9,883,329
Deferred income tax asset			955,769				831,299
Goodwill			4,779,846				5,169,661
Finite life intangibles, net			6,438,701				7,087,571
Total assets		$	75,069,712			$	76,982,626
Liabilities and Shareholders’ Equity:
Current liabilities:
Accounts payable		$	1,605,780			$	2,127,470
Accrued compensation			1,078,311				915,661
Accrued expenses			257,141				254,993
Current maturities of long-term debt			2,925,566				1,940,292
Total current liabilities			5,866,798				5,238,416
Long-term liabilities:
Other long-term liabilities			288,435				239,496
Long-term debt, less current maturities			1,002,344				3,806,185
Total long-term liabilities			1,290,779				4,045,681
Shareholders’ equity:
Common shares, no par value:
Authorized — 40,000,000
Issued and outstanding shares (12,045,367 — June 30, 2009; 11,936,586 — September 30, 2008)			55,623,287				54,223,669
Retained earnings			15,061,468				14,723,541
Accumulated other comprehensive loss			(2,772,620	)			(1,248,681	)
Total shareholders’ equity			67,912,135				67,698,529
Total liabilities and shareholders’ equity		$	75,069,712			$	76,982,626

Note — The Balance Sheet at September 30, 2008 was derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The accompanying notes are an integral part of these condensed consolidated financial statements.

ROCHESTER MEDICAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

		Three Months Ended								Nine Months Ended
		June 30,								June 30,
		2009				2008				2009				2008
Net sales		$	8,908,416			$	8,241,232			$	25,789,530			$	25,679,758
Cost of sales			4,724,893				4,568,736				13,266,735				13,594,196
Gross profit			4,183,523				3,672,496				12,522,795				12,085,562
Operating expenses:
Marketing and selling			2,541,552				2,349,911				7,555,936				6,954,582
Research and development			352,248				202,092				969,011				735,292
General and administrative			1,451,041				1,578,410				4,574,296				5,210,295
Total operating expenses			4,344,841				4,130,413				13,099,243				12,900,169
Loss from operations			(161,318	)			(457,917	)			(576,448	)			(814,607	)
Other income (expense):
Interest income			39,964				232,705				241,490				1,041,692
Interest expense			(54,586	)			(116,563	)			(218,714	)			(394,887	)
Other income			—				—				1,200,442				—
Net income (loss) before income taxes			(175,940	)			(341,775	)			646,770				(167,802	)
Income tax expense (benefit)			(99,040	)			(654,023	)			308,843				(584,746	)
Net income (loss)		$	(76,900	)		$	312,248			$	337,927			$	416,944
Net income (loss) per share — basic		$	(0.01	)		$	0.03			$	0.03			$	0.04
Net income (loss) per share — diluted		$	(0.01	)		$	0.02			$	0.03			$	0.03
Weighted average number of common shares outstanding — basic			12,025,966				11,832,240				12,029,629				11,794,733
Weighted average number of common shares outstanding — diluted			12,025,966				12,550,317				12,637,414				12,561,535

The accompanying notes are an integral part of these condensed consolidated financial statements

ROCHESTER MEDICAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

		Nine Months Ended
		June 30,
		2009				2008
Operating activities:
Net income		$	337,927			$	416,944
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation			944,464				884,333
Amortization			516,750				541,108
Stock based compensation			1,035,277				1,081,062
Deferred income tax			(291,616	)			(442,238	)
Federal tax benefit of stock options exercised			—				212,812
Changes in operating assets and liabilities:
Accounts receivable			(184,327	)			187,208
Inventories			(956,548	)			(198,275	)
Other current assets			209,291				(604,229	)
Accounts payable			(488,633	)			1,120,060
Income tax payable			76,513				(2,405,683	)
Other current liabilities			206,304				(172,109	)
Net cash provided by operating activities			1,405,402				620,993
Investing activities:
Capital expenditures			(904,101	)			(1,112,494	)
Patents			(28,321	)			(15,566	)
Purchases of marketable securities			(55,249,800	)			(51,025,697	)
Sales and maturities of marketable securities			53,975,820				52,516,875
Net cash (used in) provided by investing activities			(2,206,402	)			363,118
Financing activities:
Increase in short-term debt			2,000,000				—
Payments on long-term debt			(3,818,567	)			(1,677,978	)
Repurchase of common stock			(1,058,041	)			—
Excess tax benefit from exercises of stock options			528,928				959,523
Proceeds from issuance of common stock			893,464				861,533
Net cash (used in) provided by financing activities			(1,454,216	)			143,078
Effect of exchange rate on cash			(910,512	)			(74,851	)
Increase (decrease) in cash and cash equivalents			(3,165,728	)			1,052,338
Cash and cash equivalents at beginning of period			8,508,000				6,671,356
Cash and cash equivalents at end of period		$	5,342,272			$	7,723,694
Supplemental Cash Flow Information
Interest paid		$	254,191			$	138,586
Taxes paid		$	313,640			$	1,155,209

The accompanying notes are an integral part of these condensed consolidated financial statements

ROCHESTER MEDICAL CORPORATION

Notes to Condensed Consolidated Financial Statements (Unaudited)

June 30, 2009

Note A — Basis of Presentation

          The accompanying unaudited condensed consolidated financial statements which have been derived from the Company’s audited financial statements as of September 30, 2008 and the unaudited June 30, 2009 and 2008 condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission which include the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. These financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Form 10-K for the year ended September 30, 2008. In the opinion of management, the unaudited condensed consolidated financial statements contain all recurring adjustments considered necessary for a fair presentation of the financial position and results of operations and cash flows for the interim periods presented. The Company is not aware of any subsequent events which would require recognition or disclosure in the financial statements. Operating results for the nine-month period ended June 30, 2009 are not necessarily indicative of the results that may be expected for the year ending September 30, 2009.

Note B — Net Income (Loss) Per Share

          Net income (loss) per share is calculated in accordance with Financial Accounting Standards Board (“FASB”) Statement No. 128, Earnings Per Share. The Company’s basic net income (loss)  per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period, increased to include dilutive potential common shares issuable upon the exercise of stock options that were outstanding during the period. Diluted net loss per share is computed without consideration for any dilutive securities. A reconciliation of the numerator and denominator in the basic and diluted net income (loss) per share calculation is as follows:

		Three Months Ended								Nine Months Ended
		June 30,				June 30,				June 30,				June 30,
		2009				2008				2009				2008
Numerator:
Net income (loss)		$	(76,900	)		$	312,248			$	337,927			$	416,944
Denominator:
Basic net income (loss) per share-weighted average shares outstanding			12,025,966				11,832,240				12,029,629				11,794,733
Effect of dilutive stock options			—				718,077				607,785				766,802
Diluted net income (loss) per share-weighted average shares outstanding			12,025,966				12,550,317				12,637,414				12,561,535
Basic net income (loss) per share		$	(0.01	)		$	0.03			$	0.03			$	0.04
Diluted net income (loss) per share		$	(0.01	)		$	0.02			$	0.03			$	0.03

          Employee stock options of 270,000 and 291,250 for the third quarter of fiscal years 2009 and 2008 and 270,000 and 11,250 for the nine months ended June 30, 2009 and 2008 respectively, have been excluded from the diluted net income (loss) per share calculation because their exercise prices were greater than the average market price of the Company’s common shares and their effect would have been antidilutive. Due to the net loss in the third quarter ended June 30, 2009, diluted shares were the same as basic shares since the effect of the options would have been anti-dilutive.

Note C — Stock Based Compensation

          The Company has three stock option plans under which options have been granted to employees, including officers and directors of the Company, at a price not less than the fair market value of the Company’s common shares at the date the options were granted. Options under the 1991 Stock Option Plan are no longer granted because the 10-year granting period has expired. The granting period for the 2001 Stock Incentive Plan expires in 2011. Under the 1995 Non-Statutory Stock Option Plan, options also may be granted to certain non-employees at a price not less than the fair market value of the Company’s common shares at the date the options are granted. Options generally expire ten years from the date of grant or at an earlier date as determined by the committee of the Board of Directors of the Company that administers the plans. Options granted under the 1991, 1995 and 2001 Plans generally vest over four years from the date of grant.

          The Company accounts for share-based compensation in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 123 (Revised 2004), Share-Based Payment (“SFAS 123(R)”) which requires all share-based payments, including grants of stock options, to be recognized in the statement of operations as an operating expense based on their fair values over the requisite service period. The Company elected to utilize the modified-prospective transition method as permitted by SFAS 123(R). The Company recorded approximately $293,000 ($193,000 net of tax) and $1,035,000 ($683,000 net of tax) of related stock-based compensation expense for the quarter and nine months ended June 30, 2009, and approximately $295,000 ($195,000 net of tax) and $1,081,000 ($713,000 net of tax) of related stock-based compensation expense for the quarter and nine months ended June 30, 2008. This stock-based compensation expense reduced both basic and diluted earnings per share by $0.02 and $0.02 for the three months ended June 30, 2009 and 2008, respectively, and $0.06 and $0.06 for the nine months ended June 30, 2009 and 2008, respectively.

          As of June 30, 2009, the Company has $1,597,483 of unrecognized compensation costs related to non-vested awards that is expected to be recognized over a weighted average period of approximately fourteen months.

Stock Options

          No stock options were granted in the third quarter of fiscal 2009 or 2008.

          The following table represents stock option activity for the three months ended June 30, 2009:

						Weighted-				Weighted-
						Average				Average
		Number of				Exercise				Remaining
		Shares				Price				Contract Life
Outstanding options at beginning of period			1,702,450			$	7.14			5.83 Yrs
Granted			—				—
Exercised			(39,500	)			5.23
Canceled			(11,250	)			12.14
Outstanding options at end of period			1,651,700			$	7.15			5.75 Yrs.
Outstanding options exercisable at end of period			1,219,075			$	6.11			4.75 Yrs.

          Shares available for future stock option grants to employees and directors under existing plans were 134,500 at June 30, 2009. At June 30, 2009, the aggregate intrinsic value of options outstanding was $10,348,489, and the aggregate intrinsic value of options exercisable was $8,892,756. Total intrinsic value of options exercised was $301,898 for the three months ended June 30, 2009.

Note D — Marketable Securities

          As of June 30, 2009, the Company had $29.7 million invested in marketable securities. The marketable securities primarily consist of $27.1 million invested in U.S. treasury bills and $2.6 million invested in a mutual fund. The Company is currently reporting an unrealized loss of $743,647 related to the mutual fund as a result of the recent fluctuations in the credit markets impacting the current market value. The Company considers the current impairment in value to be temporary as it has the intent and ability to hold this investment long enough to avoid realizing any significant losses.

          Marketable securities are classified as available for sale and are carried at fair value, with unrealized gains or losses included as a separate component of shareholders’ equity. The cost and fair value of available-for-sale securities were as follows:

						Unrealized
		Cost				Loss				Fair Value
June 30, 2009		$	30,404,346			$	(743,647	)		$	29,660,699
September 30, 2008		$	28,915,366			$	(421,718	)		$	28,493,648

          Losses recognized are recorded in interest expense , in the consolidated statements of operations. Gains and losses from the sale of investments are calculated based on the specific identification method.

          Effective October 1, 2008, the Company adopted SFAS No. 157, Fair Value Measurements (“SFAS 157”), for financial assets and liabilities that are re-measured and reported at fair value at each reporting period. SFAS 157 requires that fair value measurements be classified and disclosed in one of the following three categories:

          Level 1. Quoted prices in active markets for identical assets or liabilities.

          Level 2. Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

          Level 3. Inputs that are unobservable for the asset or liability and that are significant to the fair value of the assets or liabilities.

          The adoption of SFAS 157 did not have a material impact on the Company’s consolidated financial statements. The Company has determined that the values given to its marketable securities and the values used in its goodwill impairment testing are appropriate and are based on using level 1 inputs.

Note E — Inventories

          Inventories consist of the following:

		June 30,				September 30,
		2009				2008
Raw materials		$	2,117,951			$	2,274,199
Work-in-process			3,626,561				3,375,796
Finished goods			4,069,989				3,217,830
Reserve for inventory obsolescence			(117,619	)			(121,952	)
		$	9,696,882			$	8,745,873

Note F — Income Taxes

          On a quarterly basis, the Company evaluates the realizability of its deferred tax assets and assesses the requirements for a valuation allowance. No valuation allowance has been recorded against the net deferred tax assets in 2009 or 2008 because there is sufficient future projected income as well as excess income from 2007 and 2008 to maintain that the deferred tax assets will more likely than not be able to be utilized. For the quarter ended June 30, 2009, the Company had an effective income tax rate of 47.74%. The tax rate is in line with the Company’s expectation due to the increased volume of incentive stock option activity, of which the book expense is a permanent add-back item for tax purposes. In future periods, absent of true-up entries, the Company expects the effective tax rate on U.S. income to be in the range of 40-42%, and the effective tax rate on worldwide income may fluctuate depending upon inter-company eliminations and UK operation profitability.

          The Company adopted the provisions of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, an Interpretation of SFAS No. 109 (“FIN 48”) on October 1, 2007. FIN 48 creates a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FIN 48 also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. At the adoption date, October 1, 2007, the Company did not have a material liability under FIN 48 for unrecognized tax benefits. Since adoption, the Company has recognized an approximately $288,000 increase in liability for unrecognized tax benefits.

          It is the Company’s practice to recognize penalties and/or interest to income tax matters in income tax expense. As of June 30, 2009, the Company did not have a material amount of accrued interest or penalties related to unrecognized tax benefits.

          The Company is subject to income tax examinations from time to time in the U.S. Federal jurisdiction, as well as in the United Kingdom and various state jurisdictions. The Internal Revenue Service is examining the Company’s income tax return for the fiscal year ended September 30, 2007. It is possible that this examination may be resolved within the next twelve months. Due to the potential for resolution of the Federal examination and the expiration of various statutes of limitations, it is reasonably possible that the Company’s gross unrecognized tax benefit may change. Although the outcome of this matter cannot currently be determined, the Company believes adequate provision has been made for any potential unfavorable financial statement impact.

Note G — Goodwill and Other Intangible Assets

          The Company records as goodwill the excess of purchase price over the fair value of the identifiable net assets acquired as prescribed by SFAS No. 142, Goodwill and Other Intangible Assets (“SFAS 142”). Under this standard, goodwill and intangibles with indefinite useful lives are not amortized. SFAS 142 also requires, at a minimum, an annual assessment of the carrying value of goodwill and other intangibles with indefinite useful lives. If the carrying value of goodwill or an intangible asset exceeds its fair value, an impairment loss shall be recognized. The Company tests annually for impairment on June 30th of each fiscal year or more frequently if events and circumstances indicate that the asset might be impaired. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge would be recognized by the amount that the carrying amount of the asset exceeds the fair value of the asset. The Company performed annual goodwill impairment testing by comparing the market value of the Company’s assets at June 30, 2009 to the net book value of our equity, and concluded that the goodwill was not impaired. The decrease in value of goodwill as of June 30, 2009 is strictly related to the change in foreign currency exchange rates in the United Kingdom.

Note H — Comprehensive Income (Loss)

          Comprehensive income (loss) includes net income and all other nonowner changes in shareholders’ equity during a period. The comprehensive income (loss) for the three and nine months ended June 30, 2009 and 2008 consists of the following:

		Three Months Ended								Nine Months Ended
		June 30,								June 30,
		2009				2008				2009				2008
Net income (loss)		$	(76,900	)		$	312,248			$	337,927			$	416,944
Foreign currency adjustment			2,175,107				(217,624	)			(1,417,011	)			(135,806	)
Unrealized (loss) gain on securities held			280,852				153,452				(106,928	)			(230,493	)
Comprehensive income (loss)		$	2,379,059			$	248,076			$	(1,186,012	)		$	50,645

Note I — Line of Credit and Long-Term Debt

          In June 2006, in conjunction with an asset purchase agreement with Coloplast A/S, the Company entered into an unsecured loan note deed with Coloplast with an outstanding principal amount of $5,340,000. The promissory note is non-interest bearing and payable in five equal annual installments of $1,068,000 payable annually on June 2. The Company discounted the note at 6.90% which reflected the Company’s cost of borrowing at the date of the purchase agreement and the discount is being amortized over the life of the note. The discounted liability balance was $1,927,910 at June 30, 2009.

          In June 2006, the Company entered into a $7,000,000 credit facility with U.S. Bank National Association. The credit facility consisted of a $5,000,000 term loan payable in five years and accruing interest at a rate equal to 4.77%, and a revolving line of credit of up to $2,000,000, maturing annually on March 31, with interest payable monthly at a floating rate based on the quoted one-month LIBOR rate plus 1.60%. In March 2009, the Company paid off the entire term loan and terminated the revolving line of credit.

          In February 2009, the Company entered into a $14,000,000 credit facility with UBS Financial. The credit facility consists of a revolving line of credit of up to $14,000,000 with interest accruing monthly at a floating rate based on the quoted one-month LIBOR rate plus 0.50%. As of June 30, 2009, the Company had an outstanding balance of $2,000,000 under the revolving line of credit. The Company’s obligations under the credit facility are payable on demand and are secured by its investments in marketable securities held at UBS.

Note J — Litigation Settlements

          The Company was a plaintiff in a lawsuit titled Rochester Medical Corporation vs. C.R. Bard, Inc.; Tyco International (US), Inc.; Tyco Health Care Group, L.P.; Novation LLC; VHA, Inc.; Premier, Inc.; and Premier Purchasing Partners, in the United States District Court for the Eastern District of Texas, Civil Action No. 504-CV-060. This suit alleged anti-competitive conduct against the defendants in the markets for standard and anti-infection Foley catheters as well as urethral catheters, and seeks an unspecified amount of damages and injunctive and other relief.

          On November 20, 2006, the Company announced that it had reached a settlement with Premier, Inc. and Premier Purchasing Partners, L.P. with respect to the lawsuit. Under the settlement agreement, Premier paid the Company $8,825,000 (net $5,155,000 after payment of attorneys’ fees and expenses) and was dismissed from the lawsuit.

          On December 14, 2006, the Company announced it had reached a settlement with C.R. Bard, Inc., whereby C.R. Bard, Inc. paid the Company $49,000,000 (net $33,450,000 after payment of attorneys’ fees and expenses) and was dismissed from the lawsuit.

          On August 6, 2007, the Company announced that it had reached a settlement with Novation LLC with respect to the lawsuit. Under the settlement agreement, Novation awarded the Company an Innovative Technology Contract for its urological catheter products and related accessories, including the Company’s advanced Infection Control catheters, and was dismissed from the lawsuit. The Innovation Technology Contract has a three-year term from the effective date of September 1, 2007.

          On January 15, 2009, the Company announced that it had reached a settlement with Covidien Ltd., Tyco International (US), Inc. and Tyco Health Care Group, L.P., whereby Covidien Ltd. paid the Company $3,500,000 (net $1,000,000 after payment of attorney’s fees and expenses) and was dismissed from the lawsuit. No further action is expected with respect to this lawsuit.

Note K — Share Repurchase Program

          On March 3, 2009, the Company announced its intention to repurchase some of its outstanding common shares pursuant to its previously authorized share repurchase program. Up to 2,000,000 shares may be repurchased from time to time on the open market, or pursuant to negotiated or block transactions, in accordance with applicable Securities and Exchange Commission regulations. During the three months ended June 30, 2009, no shares were repurchased. As of June 30, 2009, there remained 1,847,347 shares that may be purchased under the program.

Note L — Recently Issued Accounting Standards

          In December 2007, the FASB issued SFAS No.141 (revised 2007), Business Combinations (“SFAS 141(R)”). SFAS 141(R), among other things, establishes principles and requirements for how the acquirer in a business combination (i) recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired business, (ii) recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase, and (iii) determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS 141(R) is effective for fiscal years beginning on or after December 15, 2008, with early adoption prohibited. The Company is required to adopt SFAS 141(R) for all business combinations for which the acquisition date is on or after October 1, 2009. This standard will change the Company’s accounting treatment for business combinations on a prospective basis.

          In December 2007, the FASB issued SFAS No.160, Noncontrolling Interests in Consolidated Financial Statements, an Amendment of ARB No. 51 (“SFAS 160”). SFAS 160 establishes accounting and reporting standards for noncontrolling interests in a subsidiary and for the deconsolidation of a subsidiary. Minority interests will be recharacterized as noncontrolling interests and classified as a component of equity. It also establishes a single method of accounting for changes in a parent’s ownership interest in a subsidiary and requires expanded disclosures. SFAS 160 is effective for fiscal years beginning on or after December 15, 2008, with early adoption prohibited. The Company does not expect the adoption of SFAS 160 will have a material impact on its financial position or results of operations.

          In February 2008, the FASB issued FASB Staff Position FAS 157-2, Effective Date of FASB Statement No. 157 (“FSP FAS 157-2”). FSP FAS 157-2 defers the implementation of SFAS No. 157 for certain nonfinancial assets and nonfinancial liabilities. The portion of SFAS No. 157 that has been deferred by FSP FAS 157-2 became effective for the Company in the second fiscal quarter of fiscal year 2009. The adoption of FSP FAS 157-2 did not have a material impact on the Company’s consolidated financial statements.

          In March 2008, the FASB issued SFAS No. 161, Disclosures About Derivative Instruments and Hedging Activities, an amendment of SFAS No. 133 , which changes the disclosure requirements for derivative instruments and hedging activities. Entities will be required to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance and cash flows. This statement is effective for financial statements issued for fiscal years beginning after November 15, 2008. The Company is currently evaluating the impact of this statement.

          In April 2008, the FASB issued FSP FAS 142-3, Determination of the Useful Life of Intangible Assets (“FSP FAS 142-3”), which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under FASB Statement No. 142, Goodwill and Other Intangible Assets . FSP FAS 142-3 is effective for fiscal years beginning on or after December 15, 2008, which for the Company is the first quarter of fiscal year 2010. The Company is currently evaluating the impact the adoption of FSP FAS 142-3 will have on its consolidated financial statements.

          In April 2009, the FASB issued FSP FAS 107-1 and Accounting Principles Board (APB) 28-1, Interim Disclosures about Fair Value of Financial Instruments . The FSP amends SFAS No. 107, Disclosures about Fair Value of Financial Instruments to require an entity to provide disclosures about fair value of financial instruments in interim financial information and annual reporting periods. This FSP is to be applied prospectively and is effective for interim and annual periods ending after June 15, 2009, with early adoption permitted for periods ending after March 15, 2009. The Company has included the required disclosures in its interim financial statements for the quarter ending June 30, 2009.

          In April 2009, the FASB issued FSP FAS 115-2 and FAS 124-2, Recognition and Presentation of Other-Than-Temporary Impairments. The guidance applies to investments in debt securities for which other-than-temporary impairments may be recorded. If an entity’s management asserts that it does not have the intent to sell a debt security and it is more likely than not that it will not have to sell the security before recovery of its cost basis, then an entity may separate other-than-temporary impairments into two components: 1) the amount related to credit losses (recorded in

earnings), and 2) all other amounts (recorded in other comprehensive income). This FSP is to be applied prospectively and is effective for interim and annual periods ending after June 15, 2009, with early adoption permitted for periods ending after March 15, 2009. The Company adopted this FSP for its quarter ending June 30, 2009, with no material impact on the consolidated financial statements.

          In May 2009, the FASB issued SFAS No. 165, Subsequent Events (“SFAS 165”), which provides guidance on management’s assessment of subsequent events. The new standard clarifies that management must evaluate, as of each reporting period, events or transactions that occur after the balance sheet date through the date that the financial statements are issued or are available to be issued. SFAS 165 is not expected to significantly change practice because its guidance is similar to that in U.S. auditing literature, which the Company relied on previously for guidance on assessing and disclosing subsequent events. SFAS 165 is effective for the Company for interim periods and fiscal years beginning June 30, 2009. The Company evaluated its June 30, 2009 financial statements for subsequent events through August 8, 2009, the date the financial statements were available to be issued. The Company is not aware of any subsequent events which would require recognition or disclosure in the financial statements.

          In June 2009, the FASB issued SFAS No. 168, The FASB Accounting Standards Codification (“SFAS 168”) , which establishes the FASB’s Accounting Standards Codification as the exclusive authoritative reference for nongovernmental U.S. GAAP for use in financial statements issued for interim and annual periods ending after September 15, 2009, except for SEC rules and interpretative releases, which are also authoritative for SEC registrants. As a result, SFAS 168 replaces SFAS 162 to make all of the Codification content carry the same level of authority. The Company is currently evaluating the impact of SFAS 168, but does not expect it to have a material impact on its consolidated financial statements.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

          We develop, manufacture and market a broad line of innovative, technologically enhanced PVC-free and latex-free urinary continence and urine drainage care products for the extended care and acute care markets. Our products are comprised of our base products, which include our male external catheters and standard silicone Foley catheters, and our advanced products, which include our intermittent catheters, our anti-infection Foley catheters and our FemSoft Insert. We market our products under our Rochester Medical brand, which are referred to as branded sales, and also supply our products to several large medical product companies for sale under brands owned by these companies, which are referred to as private label sales. The primary markets for our products are distributors, extended care facilities and individual hospitals and healthcare institutions. We sell our products both in the domestic market and internationally.

          For fiscal 2009, we increased our investment in our sales and marketing programs, primarily through cash generated from current operations, to support branded sales growth in the U.S. and Europe. Our advanced products will eventually contribute a higher profit margin than our base products, and our Rochester Medical branded products contribute a higher profit margin than private label sales, particularly branded sales in the United Kingdom and elsewhere in Europe. Increasing our percentage of sales of branded products versus private label sales over time will have a positive impact on our gross margin. Branded sales accounted for 65% of total sales for the quarter ended June 30, 2009, and 65% of total sales year to date, compared to 73% for the quarter ended June 30, 2008 and 68% for the same period last year. Advanced products accounted for 14% of total sales for the quarter ended June 30, 2009, and 14% of total sales year to date, compared to 13% for the quarter ended June 30, 2008 and 12% for the same period last year.

          The following discussion pertains to our results of operations and financial position for the quarters and nine month periods ended June 30, 2009 and 2008. Results of the periods are not necessarily indicative of the results to be expected for the complete year. For the third quarter ended June 30, 2009, we reported a net loss of $0.01 per diluted share, compared to a net income of $0.02 per diluted share for the same period last year. Loss from operations was $161,000 for the quarter ended June 30, 2009 compared to a loss of $458,000 for the quarter ended June 30, 2008, with a net loss of $77,000 for the quarter ended June 30, 2009 compared to net income of $312,000 for the same period last year.

          As of June 30, 2009, we had $5.3 million in cash and cash equivalents, and $29.7 million invested in marketable securities. The marketable securities primarily consist of $27.1 million invested in U.S. treasury bills and $2.6 million invested in a mutual fund. Our investments in marketable securities are subject to interest rate risk and the value thereof

could be adversely affected due to movements in interest rates. Our investment choices, however, are conservative and are intended to reduce the risk of loss or any material impact on our financial condition. We are currently reporting an unrealized loss $743,647 related to the mutual fund as a result of the recent fluctuations in the credit markets impacting the current market value. We consider this unrealized loss temporary as we have the intent and ability to hold this investment long enough to avoid realizing any significant losses.

Results of Operations

          The following table sets forth, for the fiscal periods indicated, certain items from our statements of operations expressed as a percentage of net sales.

		Three Months Ended								Nine Months Ended
		June 30,								June 30,
		2009				2008				2009				2008
Net Sales			100	%			100	%			100	%			100	%
Cost of Sales			53	%			55	%			51	%			53	%
Gross Margin			47	%			45	%			49	%			47	%
Operating Expenses:
Marketing and Selling			29	%			29	%			29	%			27	%
Research and Development			4	%			2	%			4	%			3	%
General and Administrative			16	%			19	%			18	%			20	%
Total Operating Expenses			49	%			50	%			51	%			50	%
Loss from Operations			(2	)%			(6	)%			(2	)%			(3	)%
Interest Income (Expense), Net			0	%			2	%			0	%			2	%
Other Income, Net			0	%			0	%			5	%			0	%
Net Income (Loss) before Taxes			(2	)%			(4	)%			3	%			(1	)%
Income Tax (Expense) Benefit			0	%			(8	)%			(1	)%			(2	)%
Net Income (Loss) after Taxes			(1	)%			4	%			1	%			2	%

          The following table sets forth, for the periods indicated, net sales information by product category (base products and advanced products), marketing method (private label and Rochester Medical ^® branded sales) and distribution channel (domestic and international markets) (all dollar amounts below are in thousands):

		Fiscal Quarter Ended June 30,
		2009												2008
		Domestic				International				Total				Domestic				International				Total
Private label sales:
Base products		$	2,075			$	1,034			$	3,109			$	1,605			$	474			$	2,079
Advanced products			44				—				44				144				—				144
Total private label sales			2,119				1,034				3,153				1,749				474				2,223
Branded sales:
Base products			1,036				3,544				4,580				930				4,148				5,078
Advanced products			772				403				1,175				677				263				940
Total branded sales			1,808				3,947				5,755				1,607				4,411				6,018
Total net sales:		$	3,927			$	4,981			$	8,908			$	3,356			$	4,885			$	8,241

		Fiscal Year to Date Ended June 30,
		2009												2008
		Domestic				International				Total				Domestic				International				Total
Private label sales:
Base products		$	5,280			$	3,282			$	8,562			$	5,028			$	2,358			$	7,386
Advanced products			399				—				399				749				—				749
Total private label sales			5,679				3,282				8,961				5,777				2,358				8,135
Branded sales:
Base products			2,963				10,665				13,628				2,927				12,207				15,134
Advanced products			2,114				1,086				3,200				1,880				531				2,411
Total branded sales			5,077				11,751				16,828				4,807				12,738				17,545
Total net sales:		$	10,756			$	15,033			$	25,789			$	10,584			$	15,096			$	25,680

Three Month and Nine Month Periods Ended June 30, 2009 and June 30, 2008

           Net Sales. Net sales for the third quarter of fiscal 2009 increased 8% to $8,908,000 from $8,241,000 for the comparable quarter of last fiscal year. The sales increase primarily resulted from an increase in sales of private label products, higher sales of branded products domestically and increased branded sales internationally outside of the U.K. offset by a decrease in branded sales in the U.K. Domestic sales of branded products increased by 12.5% for the quarter compared to the same period last year. Our international branded sales decreased 10.5% compared to the same period last year, primarily as a result of the change in foreign currency exchange rates in the United Kingdom as the U.S. dollar was significantly stronger versus the pound sterling, thereby affecting total branded sales given the significant volume of our branded product sales in the United Kingdom. Private label sales were up 42% from last year, which management believes is the result of the timing of orders from large private label customers. Private label sales accounted for approximately 35% of total sales. Management continues to focus on growth in branded sales, and total branded sales volumes of intermittent catheters and Foley catheters increased for the third quarter compared to last fiscal year. In line with our strategic decision to increase investments in sales and marketing to drive growth in branded sales, we have initiated direct sales efforts into Japan and mainland Europe.

          Net sales for the nine months ended June 30, 2009 increased slightly to $25,789,000 from $25,680,000 for the comparable nine-month period of last fiscal year. The increase in sales primarily resulted from an increase in domestic private label sales and increased sales of private label products internationally and branded sales internationally outside of the U.K., offset by a decrease in branded sales in the U.K. as a result of the change in the foreign currency exchange rate in the United Kingdom of the pound sterling to the U.S. dollar from last year. Sales of branded products domestically increased 5.6% compared to the same period last year.

           Gross Margin . Our gross margin as a percentage of net sales for the third quarter of fiscal 2009 was 47% compared to 45% for the comparable quarter of last fiscal year. The increase in gross margin this quarter was primarily due to increased sales of higher margin product, including male external catheters and script easy in the U.K. and other international markets, and favorable manufacturing variances and efficiencies, partially offset by the change in the foreign currency exchange rate in the United Kingdom of the pound sterling to the U.S. dollar and increased medical claim costs. Gross margin for the nine months ended June 30, 2009 increased slightly to 49% from 47%. Factors affecting the comparative nine month gross margin are generally consistent with those discussed above for the current quarter.

           Marketing and Selling. Marketing and selling expense primarily includes costs associated with base salary paid to sales and marketing personnel, sales commissions, and travel and advertising expense. Marketing and selling expense for the third quarter of fiscal 2009 increased 8% to $2,542,000 from $2,350,000 for the comparable quarter of last fiscal year. The increase in marketing and selling expense is primarily due to increased sales personnel and related expenses incurred through the addition of sales and marketing staff in both our U.S. and U.K. operations, and increased advertising expense related to marketing in the U.K. and the U.S. of our Magic 3 intermittent catheter and preparation for our advanced Strata Foley catheter launch, partially offset by the change in the foreign currency exchange rate in the United Kingdom of the pound sterling to the U.S. dollar from last year. Marketing and selling expense as a percentage of net sales for the fiscal quarters ended June 30, 2009 and 2008 was 29% and 29%, respectively.

          Marketing and selling expense for the nine months ended June 30, 2009 increased 9% to $7,556,000 from $6,955,000 for the comparable nine-month period of last fiscal year. Factors affecting the comparative nine-month expense levels are generally consistent with those discussed above for the current quarter.

           Research and Development. Research and development expense primarily includes internal labor costs, as well as expense associated with third-party vendors performing validation and investigative research regarding our products and development activities. Research and development expense for the third quarter of fiscal 2009 increased 74% to $352,000 from $202,000 for the comparable quarter of last fiscal year. The increase in research and development expense relates primarily to increased expenses related to testing and development of new and enhanced products as we developed both our Magic3 intermittent technology and our Strata foley technology this year. Research and development expense as a percentage of net sales for the fiscal quarters ended June 30, 2009 and 2008 was 4% and 2%, respectively.

          Research and development expense for the nine months ended June 30, 2009 increased 32% to $969,000 from $735,000 for the comparable nine-month period of last fiscal year. Factors affecting the comparative nine-month expense levels are generally consistent with those discussed above for the current quarter.

           General and Administrative. General and administrative expense primarily includes payroll expense relating to our management and accounting, information technology and human resources staff, as well as fees and expenses of outside legal counsel and accounting advisors. General and administrative expense for the third quarter of fiscal 2009 decreased 8% to $1,451,000 from $1,578,000 for the comparable quarter of last fiscal year. The decrease in general and administrative expense is primarily related to decreased legal fees, audit related expenses and the change in the foreign currency exchange rate in the United Kingdom of the pound sterling to the U.S. dollar from last year. General and administrative expense as a percentage of net sales for the fiscal quarters ended June 30, 2009 and 2008 was 16% and 19%, respectively.

          General and administrative expense for the nine months ended June 30, 2009 decreased 12% to $4,574,000 from $5,210,000 for the comparable nine-month period of last fiscal year. The decrease in general and administrative expenses for the nine month period primarily reflects a decrease in legal and audit fees from the prior year.

           Interest Income. Interest income for the third quarter of fiscal 2009 decreased 83% to $40,000 from $233,000 for the comparable quarter of last fiscal year. The decrease in interest income reflects significantly lower interest rates on investments.

          Interest income for the nine months ended June 30, 2009 decreased 77% to $241,000 from $1,042,000 for the comparable nine-month period of last fiscal year. Factors affecting the comparative nine-month interest income are generally consistent with those discussed above for the current quarter.

           Interest Expense . Interest expense for the third quarter of fiscal 2009 decreased $62,000 to $55,000 from the comparable quarter of last fiscal year. The decrease in interest expense reflects lower amounts of debt as a result of quarterly debt payments and a lower effective interest rate on our debt.

          Interest expense for the nine months ended June 30, 2009 decreased $176,000 to $219,000 from $395,000 for the comparable nine-month period of last fiscal year. The decrease in interest expenses for the nine month period are generally consistent with those discussed above for the current quarter.

           Income Taxes . For the quarter ended June 30, 2009, we had an effective income tax rate of approximately 47.7%. The tax rate is in line with our expectation due to the volume of incentive stock option activity, of which the book expense is a permanent add-back item for tax purposes and increased our effective tax rate by 15% for the quarter. In future periods of taxable earnings, we expect to report an income tax provision using an effective tax rate in the range of 40 — 42% for U.S. income. The effective tax rate on worldwide income may fluctuate depending upon inter-company eliminations and U.K. operation profitability.

Liquidity and Capital Resources

          Our cash, cash equivalents and marketable securities were $35 million at June 30, 2009 compared to $37 million at September 30, 2008. The decrease in cash primarily resulted from capital expenditures, repayment of long-term debt and the repurchase of common shares offset by cash provided from operations, borrowing on our new credit facility and the sale of common shares upon exercise of options. As of June 30, 2009, we had $29.7 million invested in marketable securities as a result of the cash settlements received from lawsuits. The marketable securities primarily consist of $27.1 million invested in U.S. treasury bills and $2.6 million invested in a mutual fund. We are currently reporting an unrealized loss $743,647 related to the mutual fund as a result of the recent fluctuations in the credit markets impacting the current market value. We consider this unrealized loss temporary as we have the intent and ability to hold this investment long enough to avoid realizing any significant losses.

          During the nine-month period ended June 30, 2009, we generated $1,405,000 of cash from operating activities compared to $621,000 of cash provided by operations during the comparable period of the prior fiscal year. Increased net cash from operating activities in the first nine months of fiscal 2009 primarily reflects net income before depreciation and decreases in other current assets and increases in other current liabilities, offset by increases in inventories and decreases in accounts payable. Accounts receivable balances during this period decreased 3% or $184,000, primarily due to increased collections. Inventories increased 11% or $957,000, as we built up inventories in anticipation of our launch of our Magic 3 intermittent catheter and our advanced Strata Foley catheter. Accounts payable decreased 23% or $489,000, primarily reflecting timing of expenses. Other current liabilities increased 18% or $206,000, primarily reflecting payments of annual executive bonuses offset by timing of normal operating accruals. In addition, capital expenditures during this period were $904,000 compared to $1,112,000 for the comparable period last year.

          In June 2006, we entered into a $7,000,000 credit facility with U.S. Bank National Association. The credit facility consisted of a $5,000,000 term loan payable in five years and accruing interest at a rate equal to 4.77%, and a revolving line of credit of up to $2,000,000, maturing annually on March 31, with interest payable monthly at a floating rate based on the quoted one-month LIBOR rate plus 1.60%. In March 2009, we paid off the entire term loan and terminated the revolving line of credit.

          In February 2009, we entered into a $14,000,000 credit facility with UBS Financial. The credit facility consists of a revolving line of credit of up to $14,000,000 with interest accruing monthly at a floating rate based on the quoted one-month LIBOR rate plus 0.50%. As of June 30, 2009, we had an outstanding balance of $2,000,000 under the revolving line of credit. Our obligations under the credit facility are payable on demand and are secured by our investments in marketable securities held at UBS.

          We believe that our capital resources on hand at June 30, 2009, together with cash generated from sales, will be sufficient to satisfy our working capital requirements for the foreseeable future as described in the Liquidity and Capital Resources portion of Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended September 30, 2008. In the event that additional financing is needed, we may seek to raise additional funds through public or private financing. Any additional equity financing may be dilutive to shareholders, and debt financing, if available, may involve significant restrictive covenants. Failure to raise capital when needed could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that such financing, if required, will be available on terms satisfactory to us, if at all.

Cautionary Statement Regarding Forward Looking Information

          Statements other than historical information contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by the use of terminology such as “believe,” “may,” “will,” “expect,” “anticipate,” “predict,” “intend,” “designed,” “estimate,” “should” or “continue” or the negatives thereof or other variations thereon or comparable terminology. Such forward-looking statements involve known or unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among other things, the following:

	•		the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for our products and increased volatility in foreign exchange rates;
	•		the uncertainty of market acceptance of new product introductions;
	•		the uncertainty of gaining new strategic relationships;
	•		the uncertainty of timing of revenues from private label sales (particularly with respect to international customers);
	•		the uncertainty of successfully growing our U.K. operations and the risks associated with operating an international business;
	•		FDA and other regulatory review and response times;
	•		the securing of Group Purchasing Organization contract participation;
	•		the uncertainty of gaining significant sales from secured GPO contracts;

and other risk factors listed from time to time in our SEC reports, including, without limitation, the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended September 30, 2008.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

          Our primary financial instrument market risk results from fluctuations in interest rates. Our cash is invested in bank deposits and money market funds denominated in United States dollars and pound sterling. The carrying value of these cash equivalents approximates fair market value. Our investments in marketable securities are subject to interest rate risk and the value thereof could be adversely affected due to movements in interest rates. Our investment choices, however, are conservative in light of current economic conditions, and include primarily U.S. treasury bills to reduce the risk of loss or any material impact on our financial condition. Our revolving line of credit bears interest at a floating rate based on the quoted one-month LIBOR rate plus 0.50%. As of June 30, 2009, our revolving line of credit had a balance of $2,000,000.

          In future periods, we believe a greater portion of our revenues could be denominated in currencies other than the U.S. dollar, thereby increasing our exposure to exchange rate gains and losses on non-United States currency transactions. Sales through our subsidiary, Rochester Medical, Ltd., are denominated in pound sterling, and fluctuations in the rate of exchange between the U.S. dollar and the pound sterling could adversely affect our financial results.

          Otherwise, we do not believe our operations are currently subject to significant market risks for interest rates, foreign currency exchange rates, commodity prices or other relevant market price risks of a material nature. We do not currently use derivative financial instruments to manage interest rate risk or enter into forward exchange contracts to hedge exposure to foreign currencies, or any other derivative financial instruments for trading or speculative purposes. In the future, if we believe an increase in our currency exposure merits further review, we may consider entering into transactions to mitigate that risk.

Item 4. CONTROLS AND PROCEDURES

           Evaluation of Disclosure Controls and Procedures . As of the end of the period covered by this report (the Evaluation Date) we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended (the Exchange Act)). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

           Changes in Internal Controls . During our third fiscal quarter, there has been no change in our internal control over financial reporting (as defined in Rule 13(a)-15(f) under the Exchange Act) that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 6. Exhibits

3.1		Amended and Restated Bylaws of Rochester Medical Corporation, as amended through June 9, 2009 (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on form 8-K filed June 12, 2009).
31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
31.2		Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
32.1		Section 1350 Certification of Chief Executive Officer.
32.2		Section 1350 Certification of Chief Financial Officer.

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INDEX TO EXHIBITS

Exhibit

3.1		Amended and Restated Bylaws of Rochester Medical Corporation, as amended through June 9, 2009 (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on form 8-K filed June 12, 2009).
31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
31.2		Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
32.1		Section 1350 Certification of Chief Executive Officer.
32.2		Section 1350 Certification of Chief Financial Officer.

Rochester Medical Corp. (MM) (NASDAQ:ROCM)
Historical Stock Chart
From May 2024 to Jun 2024

Rochester Medical Corp. (MM) (NASDAQ:ROCM)
Historical Stock Chart
From Jun 2023 to Jun 2024